These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23948758)

  • 1. FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients.
    Kim MH; Koo JS; Lee S
    Oncology; 2013; 85(2):128-36. PubMed ID: 23948758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
    Liu F; Li Y; Ren M; Zhang X; Guo X; Lang R; Gu F; Fu L
    Breast Cancer Res Treat; 2012 Sep; 135(2):459-67. PubMed ID: 22842982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
    Cao AY; He M; Liu ZB; Di GH; Wu J; Lu JS; Liu GY; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3019-27. PubMed ID: 22451233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
    Ishitobi M; Okumura Y; Arima N; Yoshida A; Nakatsukasa K; Iwase T; Shien T; Masuda N; Tanaka S; Tanabe M; Tanaka T; Komoike Y; Taguchi T; Nishimura R; Inaji H
    Ann Surg Oncol; 2013 Jun; 20(6):1886-92. PubMed ID: 23292516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP3 expression and overall survival in breast cancer.
    Merlo A; Casalini P; Carcangiu ML; Malventano C; Triulzi T; Mènard S; Tagliabue E; Balsari A
    J Clin Oncol; 2009 Apr; 27(11):1746-52. PubMed ID: 19255331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
    Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
    Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
    Munzone E; Botteri E; Sciandivasci A; Curigliano G; Nolè F; Mastropasqua M; Rotmensz N; Colleoni M; Esposito A; Adamoli L; Luini A; Goldhirsch A; Viale G
    Breast Cancer Res Treat; 2012 Jul; 134(1):277-82. PubMed ID: 22467243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.
    Peurala E; Koivunen P; Bloigu R; Haapasaari KM; Jukkola-Vuorinen A
    Breast Cancer Res Treat; 2012 May; 133(1):179-88. PubMed ID: 21877141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
    Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
    Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients].
    Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
    Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
    Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer.
    Schoppmann SF; Berghoff A; Dinhof C; Jakesz R; Gnant M; Dubsky P; Jesch B; Heinzl H; Birner P
    Breast Cancer Res Treat; 2012 Jul; 134(1):237-44. PubMed ID: 22350732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.